Trade

Cohance Lifesciences share price

High risk
  • 56%Low risk
  • 56%Moderate risk
  • 56%Balanced risk
  • 56%High risk
  • 56%Extreme risk
  • 438.20(-0.62%)
    July 15, 2026 09:32:22 AM IST
    • NSE
    • BSE
  • Vol : 12.07 K (NSE + BSE)
    Last 20 day avg : 2.20 M
Cohance Lifesciences is trading -0.62% lower at Rs 438.20 as compared to its last closing price. Cohance Lifesciences has been trading in the price range of 443.05 & 436.10. Cohance Lifesciences has given -14.92% in this year & -0.71% in the last 5 days. Cohance Lifesciences has TTM P/E ratio 64.28 as compared to the sector P/E of 25.20.There are 8 analysts who have initiated coverage on Cohance Lifesciences. There are 1 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.The company posted a net profit of 19.55 Crores in its last quarter.Listed peers of Cohance Lifesciences include Cipla (0.58%), Torrent Pharmaceuticals (-0.39%), Dr Reddy's Laboratories (-0.62%).The Mutual Fund holding in Cohance Lifesciences was at 18.57% in 31 Mar 2026. The MF holding has increased from the last quarter. The FII holding in Cohance Lifesciences was at 5.59% in 31 Mar 2026. The FII holding has decreased from the last quarter.
  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Jul 15, 2026, 04:03 AM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    1.19
    High volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.10
    Higher than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.00
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    4.40
    Lower than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    96.51
    Higher than historical values
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -2.85
    Indicates undervaluation
Price range
Day Range
Lowest
436.10
Highest
443.05
52 week range
Lowest
267.85
Highest
1,121.15
Cohance Lifesciences Peers
Return Comparison
Peers Comparison
Names
Price%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Cipla
1,446.850.581,16,883.1022.953.870.870.81
Torrent Pharmaceuticals
4,951.75-0.391,67,642.0067.3217.10.8317.62
Dr Reddy's Laboratories
1,238.00-0.621,03,328.0318.633.140.632.34
Sun Pharmaceutical Industries
1,945.800.294,66,851.6036.245.770.920.50
Divi's Laboratories
7,310.301.741,94,065.4978.6111.520.460.01
Mutual Fund Ownership
View all
DSP Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 260.83
  • % of AUM 8.81
ITI Pharma and Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 10.70
  • % of AUM 4.84
Mirae Asset Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 104.34
  • % of AUM 3.88
Invesco India Focused Fund Regular Growth
5/5
  • Amount Invested (Cr.) 107.43
  • % of AUM 2.70
UTI Healthcare Fund Regular Plan Growth
NA
  • Amount Invested (Cr.) 28.14
  • % of AUM 2.65
Cohance Lifesciences Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-05-12Audited Results
2026-02-12Quarterly Results
2025-11-12Quarterly Results
2025-05-28Audited Results
2025-02-12Quarterly Results
About the company Cohance Lifesciences
  • IndustryBiotechnology & Drugs
  • ISININE03QK01018
  • BSE Code543064
  • NSE CodeCOHANCE
Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, is an India-based technology-driven contract development and manufacturing organization (CDMO), providing integrated solutions in custom synthesis, process research and development (R&D), and manufacturing. The Company’s business units include pharmaceutical CDMO, specialty chemical CDMO, and active pharmaceutical ingredient (API) (including formulations). Its integrated CDMO model enables comprehensive molecule development and life cycle management for both pharmaceutical and specialty chemical partners. Its custom synthesis services include design and synthesis, synthesis of complex molecules, synthesis of reference standards, synthesis of impurities and metabolites, scale-up of existing synthetic routes, and process optimization and backward integration. Its process research services include route scouting, process development, process safety evaluation, analytical method development, and regulatory support.
  • Management Info
  • Vivek SharmaExecutive Chairman of the Board
  • Yann D'herveChief Executive Officer
  • Himanshu AgarwalChief Financial Officer, Whole-time Director
  • Kundan JhaCompliance Officer, Company Secretary, Head- Legal
Cohance Lifesciences Share Price FAQs

Cohance Lifesciences is trading at 438.20 as on Wed Jul 15 2026 04:02:22. This is -0.62% lower as compared to its previous closing price of 440.95.

The market capitalization of Cohance Lifesciences is 16764.09 Cr as on Wed Jul 15 2026 04:02:22.

The average broker rating on Cohance Lifesciences is Hold. The breakup of analyst rating is given below -

  • 1 analysts have given a strong buy rating
  • 2 analysts have given a buy rating
  • 1 analysts have given a hold rating
  • 2 analysts have given a sell rating
  • 2 analysts have given a strong sell rating

The 52 wk high for Cohance Lifesciences is 1121.15 whereas the 52 wk low is 267.85

Cohance Lifesciences can be analyzed on the following key metrics -

  • TTM P/E: 64.28
  • Sector P/E: 25.20
  • Dividend Yield: 0.00%
  • D/E ratio: 0.10

Cohance Lifesciences reported a net profit of 179.23 Cr in 2026.

The Mutual Fund Shareholding was 18.57% at the end of 31 Mar 2026.